阿通社2月9日消息，阿联酋国务部长兼药品管理局董事会主席赛义德·本·穆巴拉克·哈杰里在2026年 世界卫生博览会期间，正式启动阿联酋药品管理局重点项目"整体国家制造项目"。该项目旨在提升本国 药品和医疗产品制造能力，强化供应链安全与产业本地化。项目在统一框架下整合了监管、制造、质量 和监督体系，覆盖原料、生产、包装、储运全链条，并支持"一体化健康"理念。阿联酋药品管理局表 示，该举措将增强产业韧性，提升制药业国际竞争力，并巩固阿联酋作为区域先进制药制造中心的地 位。 （原标题：阿联酋启动"整体国家制造项目"推动制药业发展） ...

Core Insights - Thermo Fisher Scientific, Inc. experienced a 3.50% increase in stock price, reaching its highest point since February 2025, attracting significant market attention [1] - The company's operations in Limerick, Ireland, are crucial as it is a major manufacturing hub for multinational pharmaceutical companies [1] - Recent changes in U.S. tariff policies on overseas drug production have created challenges for Thermo Fisher and similar companies, despite a reduction in tariffs from 250% to 15% [1] Company Strategies - To mitigate short-term tariff impacts, Thermo Fisher and other companies are implementing measures such as pre-exporting key raw materials and adjusting pricing strategies [2] - The high profit margins of pharmaceuticals provide a buffer against some tariff costs, but long-term challenges remain regarding U.S. policy stability and decisions on drug production locations [2] Investor Considerations - Investors should closely monitor Thermo Fisher's future strategies in global markets, particularly in the U.S., as stable policy environments and effective risk management could enhance the company's growth prospects [2] - The ongoing uncertainty in economic policies necessitates vigilance from investors to assess the impact of market and policy changes on company performance [2]